OTLK
Outlook TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
OTLK Profile
Outlook Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for various ophthalmic indications
Pharmaceutical
01/05/2010
06/14/2016
NASDAQ Stock Exchange
17
09-30
Common stock
111 S. Wood Avenue
Unit #100
Iselin
New Jersey 08852
--
Outlook Therapeutics, Inc., was incorporated in New Jersey on January 5, 2010. The company is a biopharmaceutical company that is the first to obtain marketing authorization for ONS-5010/LYTENAVA (bevacizumab-gamma) ophthalmic preparations in the EU or EU, UK or UK for the treatment of wet age-related macular degeneration, or wet AMD.
